Rivaroxaban, an anti-clotting drug from Bayer AG and Johnson & Johnson, failed to make a statistically significant difference in lowering risks of stroke, heart attack, severe recurrent chest pain and death compared with placebo in a midstage trial of patients with acute coronary syndrome. The companies plan to pursue late-stage development because overall data from the study "were persuasive enough," the lead researcher said.

Full Story:

Related Summaries